Ionis partner Roche's sefaxersen cuts proteinuria 43.1% versus placebo in Phase 3 IgAN trial

• Ionis partner Roche reported sefaxersen reduced proteinuria 43.1% versus placebo at 37 weeks in the Phase 3 IMAgINATION trial for IgA nephropathy.
• The reduction was statistically significant (95% confidence interval: 32.5%-52%; P<0.0001), with consistent treatment effects across all prespecified subgroups.
• Sefaxersen, an investigational monthly injection designed for self-administration, was well tolerated, with no new safety signals.
• The blinded trial will continue to assess kidney function at week 105; Roche plans to share results with health authorities.
• The licensing agreement provides eligibility for regulatory and sales milestone payments, plus tiered royalties on sefaxersen net sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ionis Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-040631), on October 23, 2026, and is solely responsible for the information contained therein.